To identify the circulating T cell subsets associated with effective checkpoint therapy, we isolated CD4+ and CD8+ T cells from the peripheral blood on day 18 post MC-38 tumor challenge of treated (anti-PD-L1, anti-OX40/CpG, and PDOX) and untreated mice. This evidence concerns the gene CD8A and neoplasm.